MSC therapy for chronic ischemic cardiomyopathy — cardiac repair and LVEF improvement

Chronic ischemic cardiomyopathy affects an estimated 2–5 million people in the United States alone, making it one of the most prevalent causes of heart failure with reduced ejection fraction (HFrEF). [1] The scarred, thinned ventricular wall that follows one or more myocardial infarctions progressively loses its ability to pump, and guideline-directed medical therapy — while life-extending — does not reverse the structural damage.

Where conventional therapy reaches its ceiling. Beta-blockers, ACE inhibitors, mineralocorticoid receptor antagonists, and device therapy (ICDs, CRT) slow the downward trajectory, but patients continue to accumulate myocardial scar, and a substantial proportion progress to end-stage disease despite optimal management. The gap is structural: no drug regrows contractile tissue.

The problem is the scar. After myocardial infarction, necrotic cardiomyocytes are replaced by a collagen-rich extracellular matrix that neither contracts nor conducts. This fibrotic replacement stabilises the ventricular wall acutely but becomes pathological when it expands — a process termed adverse ventricular remodelling — leading to progressive chamber dilation, worsened wall stress, and functional mitral regurgitation. [2]

MSCs target the scar microenvironment. Rather than attempting to replace dead cardiomyocytes directly, mesenchymal stem cells secrete a broad repertoire of paracrine factors — including VEGF, HGF, IGF-1, and TGF-β modulators — that collectively reduce fibrosis, stimulate resident cardiac progenitor activity, promote angiogenesis in the peri-infarct border zone, and suppress maladaptive inflammation. [3] This multi-target mechanism is well-suited to the complex pathophysiology of ischemic cardiomyopathy.

What Is Chronic Ischemic Cardiomyopathy?

Chronic ischemic cardiomyopathy is a distinct form of heart failure caused by coronary artery disease that has produced irreversible myocardial damage. It is defined by left ventricular systolic dysfunction (LVEF ≤ 40%) attributable to ischemia, with evidence of prior myocardial infarction, hibernating myocardium, or both. [4]

The condition differs from non-ischemic dilated cardiomyopathy in both pathophysiology and prognosis. Because the underlying driver is atherosclerotic coronary disease, the myocardial injury tends to be regional and patchy rather than global, and interventions that improve coronary perfusion (revascularisation) can recover some function in hibernating segments. However, once fibrotic scar has formed, that tissue is permanently non-contractile.

Clinically, patients present with the classic heart failure syndrome — exertional dyspnoea, orthopnoea, paroxysmal nocturnal dyspnoea, fatigue, and peripheral oedema — superimposed on a history of angina, prior MI, or coronary revascularisation. Diagnosis rests on echocardiography demonstrating regional wall motion abnormalities in a coronary distribution, supported by stress testing, cardiac MRI with late gadolinium enhancement confirming transmural or subendocardial scar, and coronary angiography documenting the culprit lesions.

How MSCs May Help Ischemic Cardiomyopathy

MSC therapy for chronic ischemic cardiomyopathy operates through four interconnected mechanisms, none of which requires the transplanted cells to become new cardiomyocytes. [5]

Paracrine signalling. MSCs secrete a rich cocktail of growth factors and cytokines — VEGF, HGF, IGF-1, SDF-1, and angiopoietin-1 — that act on the host myocardium. VEGF stimulates angiogenesis in the ischaemic border zone, recruiting new capillary networks that improve oxygen delivery to hibernating but viable tissue. HGF and IGF-1 activate resident cardiac stem cells and promote cardiomyocyte survival. This "bystander effect" is now considered the dominant mechanism of MSC benefit in the heart. [6]

Anti-fibrotic remodelling. MSCs modulate the TGF-β/Smad signalling axis and secrete matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in a balanced ratio that favours scar resorption over expansion. Preclinical models consistently show reduced collagen volume fraction in MSC-treated hearts, with improved ventricular compliance and reduced end-diastolic pressure. [7]

Immunomodulation. The post-infarction myocardium is a pro-inflammatory environment driven by M1 macrophages, IL-1β, IL-6, and TNF-α. MSCs polarise macrophages toward the reparative M2 phenotype, expand regulatory T-cell populations, and suppress neutrophil infiltration — shifting the milieu from chronic destructive inflammation toward tissue repair. [8]

Angiogenesis and perfusion. Beyond VEGF secretion, MSCs differentiate into pericyte-like cells that stabilise nascent vessels, and their exosomes carry microRNAs (miR-21, miR-210) that promote endothelial cell proliferation and tube formation. Together, these effects improve microvascular density in peri-infarct regions — a parameter that correlates with functional recovery on serial echocardiography. [9]

What the Clinical Trials Show

The clinical evidence for MSC therapy in ischemic cardiomyopathy comes from a series of phase I/II trials. While results are mixed and modest, they establish a safety foundation and signal of potential benefit.

Key Clinical Trials in Ischemic Cardiomyopathy — Summary

  • POSEIDON (2012). 30 patients with ischemic cardiomyopathy randomised to autologous vs allogeneic bone-marrow MSCs via transendocardial injection. Both groups showed improved 6-minute walk distance and reduced infarct size on CT at 13 months. Allogeneic MSCs were not immunogenic. [10]
  • TAC-HFT (2014). 65 patients comparing MSC vs bone marrow mononuclear cells. MSC group showed significantly greater reduction in infarct size (−18.9% vs −7.0%, p=0.05) and improved regional contractility at 12 months. [11]
  • MSC-HF (2015). 60 patients with severe ischemic HF (LVEF <45%) randomised to intramyocardial autologous bone-marrow MSCs vs placebo. MSC group showed mean LVEF improvement of +6.2% (placebo: −1.4%, p<0.001) and reduced end-systolic volume at 6 months. [12]
  • DREAM-HF (2023). 537 patients with HFrEF (60% ischemic) randomised to transendocardial allogeneic MPCs (rexlemestrocel-L) vs sham control. Did not meet primary endpoint of recurrent HF hospitalisations, but pre-specified analysis showed 24% reduction in cardiac death/MI/stroke composite in the treated group. Safe across the cohort. [13]
  • CHART-1 (2016). 315 patients with ischemic HF receiving cardiopoietic bone-marrow cells vs sham. Negative for primary endpoint, but post hoc analysis suggested benefit in patients with baseline LVEDV 200–370 mL. Underscores the importance of patient selection. [14]

The consistent pattern across these trials is reassuring safety — no excess arrhythmias, no tumour formation — with modest but statistically significant improvements in surrogate endpoints (LVEF, infarct size, 6MWD) that have not yet translated into a definitive mortality or hospitalisation benefit. The field is in a phase of refining cell product, dose, delivery route, and patient selection to amplify the signal.

How Outcomes Are Measured

Understanding the cardiac imaging and biomarker endpoints used in MSC trials is essential for evaluating claims. [15]

LVEF (Left Ventricular Ejection Fraction). The percentage of blood ejected from the left ventricle with each contraction. Measured by echocardiography or cardiac MRI. Normal ≥ 52% (male) or ≥ 54% (female). In the MSC-HF trial, treated patients gained a mean of 6.2 LVEF percentage points over 6 months — a modest but clinically meaningful change.

Infarct Size / Scar Burden. Quantified by late gadolinium enhancement (LGE) on cardiac MRI. This is arguably the most direct measure of MSC anti-fibrotic effect. TAC-HFT reported an 18.9% relative reduction in infarct size in the MSC arm.

LV Volumes (LVEDV, LVESV). Left ventricular end-diastolic and end-systolic volumes track adverse remodelling. A decrease in LVESV (reverse remodelling) is a positive prognostic sign and has been observed across multiple MSC trials.

6-Minute Walk Distance (6MWD). A simple, reproducible functional endpoint. Improvements of 30–50 metres reached statistical significance in POSEIDON and other early-phase trials.

NT-proBNP. A natriuretic peptide biomarker that reflects ventricular wall stress. Reductions in NT-proBNP correlate with improved haemodynamics and are an established surrogate in heart failure trials. [16]

Delivery Routes: Intravenous vs Intramyocardial

How MSCs reach the heart matters profoundly. The two principal routes each carry distinct advantages and limitations.

Intramyocardial injection — typically via transendocardial catheter (NOGA mapping) or direct surgical injection during CABG — deposits cells directly into the peri-infarct zone, bypassing the pulmonary first-pass trap that captures 80–90% of intravenously delivered cells. This is the preferred route in most major trials (POSEIDON, TAC-HFT, MSC-HF, DREAM-HF). The trade-off is invasiveness and the requirement for specialised mapping equipment.

Intravenous infusion is simpler, repeatable, and suitable for ambulatory care, but the lung trapping means only a small fraction of cells reach the coronary circulation. Some investigators argue this is acceptable because the paracrine effect may be systemic rather than local, and trapped MSCs in the pulmonary microvasculature still secrete anti-inflammatory factors that enter the systemic circulation. This hypothesis remains unproven. [17]

Key Takeaway

The largest and most rigorously controlled trials in ischemic cardiomyopathy have used direct intramyocardial delivery. IV delivery for cardiac indications lacks comparable phase III evidence. When evaluating a treatment proposal, ask which delivery route is planned and what published evidence supports that specific route for the patient's condition.

Patient Selection: Who Stands to Benefit Most?

Not all patients with ischemic cardiomyopathy are equally likely to respond to MSC therapy. Post hoc analyses from the larger trials point to several predictors of response. [18]

Limitations and Honest Caveats

What MSC therapy cannot do — yet

  • No MSC product is FDA-approved or EMA-approved for ischemic cardiomyopathy as of 2026. All use is investigational.
  • The largest phase III trial (DREAM-HF, n=537) did not meet its primary endpoint. The signals are in secondary and subgroup analyses.
  • LVEF improvements in the positive trials are modest (mean +3–6 percentage points) — not "reversal" of heart failure.
  • MSCs do not regenerate substantial volumes of new myocardium. The benefit is paracrine, not cardiomyogenic.
  • Long-term durability beyond 12–24 months is under-studied. Most trials report at 6–12 months.
  • Patient-level predictors of response are statistical associations, not validated biomarkers. Individual response is variable.

These limitations do not mean the approach is invalid — many therapies for chronic diseases produce modest, incremental benefits that are nonetheless clinically meaningful. But they define the honest boundaries of current knowledge.

VELAR's Approach

At VELAR Center, we approach ischemic cardiomyopathy with the same principles that guide all our regenerative protocols: transparency about the evidence, conservative claims, and integration with — never replacement of — conventional cardiology care.

Our MSC protocols for cardiac patients are grounded in the paracrine biology described above. We use Wharton's jelly-derived MSCs, which have a more potent secretory profile than adult bone-marrow MSCs, with higher expression of VEGF, HGF, and anti-inflammatory cytokines. All cells are processed in our ISO 9001-certified laboratory with full batch traceability. For patients with ischemic cardiomyopathy, our clinical team reviews cardiac imaging, ejection fraction, NYHA class, and medication regimen before determining suitability — and we require that patients maintain their guideline-directed medical therapy throughout the regenerative protocol.

We do not claim to reverse heart failure, regrow dead muscle, or replace cardiology care. What we offer is a biologically rational adjunct grounded in acknowledged paracrine mechanisms, delivered with the transparency that an investigational field demands.

Frequently Asked Questions

Can stem cells regrow dead heart muscle after a heart attack?

No. Current evidence does not support the claim that MSCs become large numbers of new cardiomyocytes. The benefit — when it occurs — is paracrine: MSCs secrete factors that reduce scar, promote angiogenesis, and suppress inflammation in the surviving border zone. This is tissue support, not tissue replacement.

How much LVEF improvement can I realistically expect from MSC therapy?

In the clinical trials that showed benefit (MSC-HF, TAC-HFT), the mean LVEF improvement was 3–7 percentage points over 6–12 months. This is a modest but clinically meaningful change for patients with moderate dysfunction. Responses vary; some patients experience no measurable improvement.

Is MSC therapy safe for patients with ICDs or pacemakers?

Yes. No trial has reported an excess of arrhythmic events or device interactions with MSC therapy. The arrhythmia rate in treated groups has been comparable to placebo across all major trials — one of the strongest safety signals in the field.

How is MSC therapy delivered to the heart — IV or injection?

In the major clinical trials (POSEIDON, DREAM-HF, MSC-HF), cells were delivered by transendocardial catheter injection under electromechanical mapping — a catheter-based procedure that deposits cells directly into the heart wall. IV delivery is simpler but results in pulmonary trapping of most cells and has substantially less clinical evidence for cardiac indications.

How much does stem cell therapy for heart failure cost in Thailand?

Costs vary by protocol complexity, cell dose, and number of sessions. At VELAR Center, a cardiac MSC protocol typically ranges from USD 15,000–25,000 depending on individual assessment. This is a fraction of comparable protocols in the United States or Europe, where costs frequently exceed USD 40,000. All prospective patients receive a detailed cost breakdown during the consultation process.

Will I still need my heart failure medications during MSC therapy?

Absolutely. MSC therapy is an adjunct, not a replacement, for guideline-directed medical therapy. Beta-blockers, ACE inhibitors/ARBs, MRAs, and SGLT2 inhibitors remain the foundation of heart failure management. MSCs are studied as a supplement to — never a substitute for — these proven treatments.

References

  1. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics — 2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56-e528. doi:10.1161/CIR.0000000000000659 ↩
  2. Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circulation Research. 2016;119(1):91-112. doi:10.1161/CIRCRESAHA.116.303577 ↩
  3. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circulation Research. 2008;103(11):1204-1219. doi:10.1161/CIRCRESAHA.108.176826 ↩
  4. Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. Journal of the American College of Cardiology. 2002;39(2):210-218. doi:10.1016/S0735-1097(01)01738-7 ↩
  5. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circulation Research. 2011;109(8):923-940. doi:10.1161/CIRCRESAHA.111.243147 ↩
  6. Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012;10(3):244-258. doi:10.1016/j.stem.2012.02.005 ↩
  7. Mias C, Lairez O, Trouche E, et al. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells. 2009;27(11):2734-2743. doi:10.1002/stem.169 ↩
  8. Ben-Mordechai T, Holbova R, Landa-Rouben N, et al. Macrophage subpopulations are essential for infarct repair with and without stem cell therapy. Journal of the American College of Cardiology. 2013;62(20):1890-1901. doi:10.1016/j.jacc.2013.07.057 ↩
  9. Bian S, Zhang L, Duan L, Wang X, Min Y, Yu H. Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. Journal of Molecular Medicine. 2014;92(4):387-397. doi:10.1007/s00109-013-1110-5 ↩
  10. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369-2379. doi:10.1001/jama.2012.25321 ↩
  11. Heldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014;311(1):62-73. doi:10.1001/jama.2013.282909 ↩
  12. Mathiasen AB, Qayyum AA, Jørgensen E, et al. Bone marrow–derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). European Heart Journal. 2015;36(27):1744-1753. doi:10.1093/eurheartj/ehv136 ↩
  13. Perin EC, Borow KM, Henry TD, et al. Randomized trial of targeted transendocardial mesenchymal precursor cell therapy in patients with heart failure. Journal of the American College of Cardiology. 2023;81(9):849-863. doi:10.1016/j.jacc.2022.11.061 ↩
  14. Bartunek J, Terzic A, Davison BA, et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. European Heart Journal. 2017;38(9):648-660. doi:10.1093/eurheartj/ehw543 ↩
  15. Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circulation Research. 2013;113(6):810-834. doi:10.1161/CIRCRESAHA.113.300219 ↩
  16. Januzzi JL, Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation. 2013;127(4):500-508. doi:10.1161/CIRCULATIONAHA.112.120485 ↩
  17. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54-63. doi:10.1016/j.stem.2009.05.003 ↩
  18. Banerjee MN, Bolli R, Hare JM. Clinical studies of cell therapy in cardiovascular medicine: recent developments and future directions. Circulation Research. 2018;123(2):266-287. doi:10.1161/CIRCRESAHA.118.311217 ↩